Contribute Try STAT+ Today

After weeks of anticipation, Jacobus Pharmaceutical, a small, family-run drug maker, has priced its rare disease drug at $80 a tablet, or less than half the price of a similar pill sold by its upstart rival, Catalyst Pharmaceuticals (CPRX). And the move is likely to set up a closely watched battle amid what is already one of the more unusual pharmaceutical tales of the year.

At issue are rival treatments for Lambert-Eaton myasthenic syndrome, or LEMS. Last month, the Food and Drug Administration approved the Jacobus drug for children ages 6 to 17, potentially adding unforeseen competition for Catalyst, which only last November won an FDA endorsement to market its own treatment for adults.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.